ANAPTYSBIO INC. - COMMON STOCK

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

05 11 2024 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Participation in November and December Investor Conferences

05 11 2024 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Participation in September Investor Conferences

29 8 2024 09:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

14 8 2024 05:00:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

05 8 2024 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

09 5 2024 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

09 5 2024 16:10:00 提供 Nasdaq GlobeNewswire

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

09 5 2024 16:05:01 提供 Nasdaq GlobeNewswire

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

11 3 2024 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

29 2 2024 09:15:00 提供 Nasdaq GlobeNewswire

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

31 1 2024 09:15:00 提供 Nasdaq GlobeNewswire

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

27 11 2023 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Named a BioSpace 2024 Best Places to Work Winner

07 11 2023 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

02 11 2023 16:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Participation in November Investor Conferences

01 11 2023 09:15:00 提供 Nasdaq GlobeNewswire

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

11 10 2023 09:15:00 提供 Nasdaq GlobeNewswire

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

09 10 2023 08:15:00 提供 Nasdaq GlobeNewswire

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

09 10 2023 08:00:00 提供 Nasdaq GlobeNewswire

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

18 9 2023 16:15:00 提供 Nasdaq GlobeNewswire

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

12 9 2023 09:15:00 提供 Nasdaq GlobeNewswire